A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity
Status:
Recruiting
Trial end date:
2025-08-31
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, Open-label Phase 3 clinical study comparing the efficacy
and safety of IBI362 6 mg OW versus Semalgutide 1 mg OW in obese(BMI≥28kg/m2) early T2D
subjects. Subjects will be randomly assigned to IBI362 6 mg and Semalgutide 1 mg groups. All
study treatment will be administered once-weekly and subcutaneously. The entire trial cycle
includes a 2-week screening period, a 40-week double-blind treatment period, and a 4-week
drug withdrawal safety follow-up period